Researchers have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating ...

Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

Dr. Laura Finn brings new treatment options to Louisiana using genetically altered cells to treat blood cancer patients. Here ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

Former Bachelorette star Katie Thurston is sharing a major update on her cancer journey after having to put her treatments on ...

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

BioLife has improved its financials, with a dominant 70% market share in biopreservation media and high gross margins. Read why I'm neutral on BLFS stock.

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...